Drugs / FVIII
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01458106 | Nov 2012 → Dec 2013 | hemophilia A | Bioverativ Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FVIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01458106 ↗ |
| Route | Intravenous | “participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg” NCT01458106 ↗ |